Immune Function Monitoring and Immunotherapy in Sepsis

• Conditions: Sepsis; Septic Shock

• Registration Number: NCT04903405
• Lead Sponsor: Sun Yat-sen University

Brief Summary

At present, the clinical studies of various anti-inflammatory drugs and immune-enhancing drugs show that immunotherapy will bring new hope for the treatment of sepsis. In order to further understand the current status of immunotherapy in China, this study aims to understand the current status and standardization of the use of sepsis immunosurveillance and immunotherapy in hospitals through a cross-sectional survey.

Detailed Description

Not available

Study Timeline

• Status Verified: 2021-05
• Study First Submitted: 2021-05-23
• Study First Submitted QC: 2021-05-23
• Last Update Submitted: 2021-05-23
• Study First Posted: 2021-05-26
• Last Update Posted: 2021-05-26
• Study Start: 2021-06-01
• Primary Completion: 2021-06-30
• Study Completion: 2021-07-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

• Patients with sepsis or septic shock according to Sepsis 3.0

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28-day mortality	28 days

Secondary Outcome Measures

Name	Time	Method
Percentage of sepsis patients receiving immune function monitoring	28 days
Percentage of sepsis patients receiving immunotherapy	28 days